Quantcast

Pulmonary Drug Delivery Systems Market Expected to Reach USD 28.7 Billion Globally in 2019: Transparency Market Research

February 25, 2014

ALBANY, New York, February 25, 2014 /PRNewswire/ –

According to a new market report published by Transparency Market Research “Pulmonary
Drug Delivery Systems Market(Products- Metered Dose Inhalers, Dry Powder Inhalers and
Nebulizers; Applications- Asthma, COPD and Cystic Fibrosis) – Global Industry Analysis,
Size, Share, Growth, Trends and Forecast, 2013 – 2019,” the global pulmonary drug delivery
systems market was valued at USD 21.03billion in 2012 and is expected to grow at a CAGR
of4.5% from 2013 to 2019, to reach an estimated value of USD 28.70billion in 2019.

Browse Global Pulmonary Drug Delivery Systems Market Report with Full TOC at

http://www.transparencymarketresearch.com/pulmonary-drug-delivery-systems.html

Pulmonary drug delivery systems use the respiratory tract to deliver medications to
treat diseases such as asthma, chronic obstructive pulmonary disease (COPD) and cystic
fibrosis. The history of use of these systems dates back to over 60 years ago, when these
systems were initially indicated for treating only respiratory diseases – asthma and COPD.
Continued development in this area facilitated their application in the treatment of other
diseases as well, including cystic fibrosis and diabetes. Exubera was the first inhalable
insulin launched by Pfizer Ltd. and Nektar Pharma for treating diabetes, in 2006.
However,owing to its poor sales performance, Exubera was withdrawn from the market within
a yearof its launch which led other partnerships such as Alkermes/Eli Lilly and
Aradigm/Novo Nordisk to abandon the development process of inhalable insulin therapies.
Currently,Afrezza by MannKind Corporation is the only inhalable insulin under review by
the U.S. FDA and is likely to be approved for marketing in the U.S. by mid-2014.

The global market for pulmonary drug delivery systems includes metered dose inhalers
(MDIs), dry powder inhalers (DPIs) and nebulizers. Initially, MDIs used
chlorofluorocarbons (CFCs) as propellants.Later due to rising environmental concerns and
pressure from Montreal Protocol (1987) recommendation to phase out CFCs, manufacturers
started using hydrofluoroalkanes (HFAs) that are considered as safe propellants causing
negligible threat ofozone depletion.MDIs accounted for the largest share (56.8%) of the
total global pulmonary drug delivery systems market in 2012 and this segment is expected
to grow at a CAGR relatively lower than that for DPIs and nebulizer market segments. This
is primarily because of the environmental concerns related with the use of CFCs, which led
to ban on CFC-based inhalers. Although manufacturers have now started using HFAs the fact
that HFAs also emit gases causing ozone layer depletion has led manufacturers to shift
their focus more towards the development of DPIs. During the forecast period 2013 to 2019,
DPIs are expected to witness greater demand than MDIs owing to propellant free nature of
these systems. The market for nebulizers has been anticipated as the fastest growing
segment of the pulmonary drug delivery systems market mainly due to the technical advances
leading to portability of these devices and rising demand for home based care. The global
pulmonary drug delivery systems market has also been segmented on the basis of their
application in treating various diseases such as asthma, COPD and cystic fibrosis.

Among the four major geographies of the world, North America and Europe accounted for
the first and second largest market shares in 2012 of the global pulmonary drug delivery
systems market.The market in these regions is characterized by a range of factors such as
patent expiry of many blockbuster inhaler brands, increasing prevalence of asthma and
COPD, focus on reducing treatment costs, growing environmental concerns and aging
population.Asia-Pacific held the third largest share of the global pulmonary drug delivery
systems market in 2012. The region being home to more than half of the world’s population
represents a large pool of patients suffering from respiratory diseases such as asthma and
COPD, and thus, represents a high growth potential market for pulmonary drug delivery
systems, estimated to grow at a CAGR of 6.6% during the forecast period.Emerging economies
of India and China are expected to favor the positive growth of pulmonary drug delivery
systems market in the region by contributing to the rise in healthcare expenditure.

Related & Recently Published Reports by Transparency Market Research

        - Sports Medicine Devices Market:

http://www.transparencymarketresearch.com/sports-medicine-device-market.html

        - Defibrillators Market:

http://www.transparencymarketresearch.com/defibrillators-market.html

        - Polypropylene Market:

http://www.transparencymarketresearch.com/polypropylene-market.html

        - Distribution Automation Market:

http://www.transparencymarketresearch.com/distribution-automation-market.html

        - Aerial Imaging Market:

http://www.transparencymarketresearch.com/aerial-imagery-market.html

        - Continuous Glucose Monitoring Market:

http://www.transparencymarketresearch.com/continuous-glucose-monitoring.html

        - Industrial Protective Footwear Market:

http://www.transparencymarketresearch.com/industrial-protective-footwear.html

        - Rapid Medical Diagnostic Kits Market:

http://www.transparencymarketresearch.com/rapid-medical-diagnostic-kits.html

        - Colored PU Foams Market:

http://www.transparencymarketresearch.com/colored-pu-foams-market.html

The global market for pulmonary drug delivery systems is dominated by companies such
as GlaxoSmithKline, plc, Boehringer Ingelheim, AstraZeneca, Merck & Co., Philips
Respironics and Omron Healthcare. These players collectively accounted for more than 75%
of the global pulmonary drug delivery systems market revenue in 2012.Some other players
operating in this market include Novartis AG, CareFusion Corporation, 3M Health Care, PARI
Respiratory Equipment, Inc., Sunovion Pharmaceuticals Inc., Allied Healthcare Products,
Inc., and GF Health Products Inc.

The global pulmonary drug delivery systems market
[http://www.transparencymarketresearch.com/pulmonary-drug-delivery-systems.html ] is
segmented as follows:

Pulmonary Drug Delivery Systems Market, by Product Type

        - Metered Dose Inhalers (MDIs)
        - Dry Powder Inhalers (DPIs)
        - Nebulizers

Pulmonary Drug Delivery Systems Market, by Application

        - Asthma
        - Chronic Obstructive Pulmonary Disease (COPD)
        - Cystic Fibrosis

Pulmonary Drug Delivery Systems Market, by Geography

        - North America
        - Europe
        - Asia-Pacific
        - Rest of the World (RoW)

Browse all Medical Devices Market Research Reports @

http://www.transparencymarketresearch.com/medical-devices-market-reports-6.html

About Us

Transparency Market Research is a global market intelligence company, providing global
business information reports and services. Our exclusive blend of quantitative forecasting
and trends analysis provides forward-looking insight for thousands of decision makers. We
are privileged with highly experienced team of Analysts, Researchers, and Consultants, who
use proprietary data sources and various tools and techniques to gather, and analyze
information.

Our data repository is continuously updated and revised by a team of research experts,
so that it always reflects the latest trends and information. With a broad research and
analysis capability, Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research material for business
reports.

Contact

Sheela AK

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Web: http://www.transparencymarketresearch.com

Blog: http://www.tmrblog.com

Blog: http://transparencymarketresearch.areavoices.com

SOURCE http://www.transparencymarketresearch.com/


Source: PR Newswire



comments powered by Disqus